The US Food and Drug Administration’s handling of the authorization allowing emergency use of hydroxychloroquine and chloroquine for treatment of COVID-19 will inevitably be viewed as a test of the agency’s independence in the context of the Trump Administration.
The 15 June revocation of the EUA granted for the products will certainly weigh heavily in favor of FDA’s independence...